Novartis v. Natco Pharma: KISQALI® Ribociclib Patent Dismissed With Prejudice
Novartis AG and Astex Therapeutics Ltd. filed suit against Natco Pharma in Delaware over US9868739B2, the patent covering KISQALI® (ribociclib) tablets used in breast cancer treatment. The parties jointly stipulated to dismiss all claims with prejudice after just 139 days — each bearing its own legal costs.
A Swift ANDA Settlement: KISQALI® Patent Dispute Ends in 139 Days
On December 13, 2024, Novartis AG and co-plaintiff Astex Therapeutics Ltd. filed an infringement action in the U.S. District Court for the District of Delaware against Natco Pharma Limited, Natco Pharma, Inc., and Natco Pharma USA LLC. The suit asserted US9868739B2, a patent covering ribociclib — the active pharmaceutical ingredient in Novartis’s blockbuster breast cancer therapy KISQALI® — against what the complaint characterised as Natco’s ANDA-driven generic entry threat.
The case closed on May 1, 2025, when the parties filed a joint stipulation pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all claims with prejudice. Each party agreed to bear its own attorneys’ fees and costs. Dismissal with prejudice is a final adjudication on the merits under res judicata principles, meaning Novartis and Astex are barred from reasserting the same claims against Natco on US9868739B2 in future proceedings.
A 139-day resolution is notably short for Hatch-Waxman ANDA litigation, which typically triggers an automatic 30-month stay and plays out over multiple years. The rapid exit — combined with a mutual cost-bearing arrangement and no public settlement terms — is consistent with a confidential commercial resolution, though the public record does not confirm this. What drove the dismissal, whether a license, covenant not to sue, or other agreement, remains undisclosed.
Filing to Dismissed with Prejudice in 139 days
139 days — resolved well under the median ANDA patent litigation timeline of 2–3 years
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41(a)(1)(A)(ii) dismissal with prejudice explained
A stipulated dismissal under FRCP 41(a)(1)(A)(ii) requires both parties’ signatures and, when filed with prejudice, operates as a final judgment on the merits. Novartis and Astex cannot re-file identical infringement claims against Natco on US9868739B2 in any U.S. federal court. No judicial fact-finding occurred — the case ended entirely by party agreement.
Res judicata appliesNovartis relinquishes the right to re-sue Natco on this patent
By stipulating to dismissal with prejudice, Novartis and Astex permanently closed the door on reasserting US9868739B2 against Natco on the same claims. In practice, this is a significant concession unless offset by a private agreement — such as a license, consent judgment, or market entry date — that protects KISQALI® commercial exclusivity in a way the public record does not reveal.
Cannot refile on US9868739B2Natco achieves finality — but terms of any deal are undisclosed
Natco secured a permanent bar against Novartis re-litigating the same patent claims. Whether this translates into a near-term right to launch a generic ribociclib product depends on any private side agreement. The absence of a court-ordered injunction or consent judgment in the public record leaves Natco’s commercial position ambiguous to outside observers.
Litigation risk eliminatedKISQALI® exclusivity landscape remains uncertain for competitors
KISQALI® is a high-revenue CDK4/6 inhibitor. A rapid with-prejudice dismissal in Hatch-Waxman litigation typically signals a negotiated resolution. Other generic filers watching US9868739B2 should note the patent’s enforceability was never tested on the merits here. Novartis may still hold additional KISQALI® patents capable of supporting fresh infringement actions against other ANDA applicants.
Monitor KISQALI® patent portfolioFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Global pharmaceutical innovator — holder of US9868739B2 (KISQALI® ribociclib)Search in Eureka ↗ |
| Defendant | Natco Pharma, Ltd. | Company | Indian generic pharmaceutical manufacturer and its U.S. subsidiaries pursuing ANDA approvalSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal is signed by both parties and filed under Rule 41(a)(1)(A)(ii), confirming mutual consent. The with-prejudice designation is expressly stated, making this a final disposition on the merits for preclusion purposes. Notably, the cost-sharing clause — each party bearing its own fees — suggests neither side extracted a clear litigation win, which is consistent with an underlying negotiated resolution whose terms were not placed on the public record by Judge Hall.
US9868739B2 — Ribociclib CDK4/6 Inhibitor Compound (KISQALI®)
US9868739B2, filed under application number US14/887790, covers ribociclib — the active pharmaceutical ingredient in Novartis’s KISQALI® tablets. Ribociclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. CDK4/6 inhibitors represent a major pharmacological advance in oncology, and patent protection over the core compound is commercially critical to sustaining brand exclusivity against generic ANDA challengers.
US9868739B2 sits at the heart of the Hatch-Waxman exclusivity framework for KISQALI®. Because its merits were never adjudicated in this action, its validity and claim scope remain untested in court. Competitor pharmaceutical companies and generic manufacturers targeting the CDK4/6 inhibitor space should treat this patent as an active enforcement risk. Novartis and co-owner Astex Therapeutics retain the ability to assert it against any ANDA filer not covered by the Natco-specific with-prejudice bar.
Should your R&D team run an FTO against US9868739B2?
Any pharmaceutical developer, generic manufacturer, or biosimilar entrant working on CDK4/6 inhibitors — particularly ribociclib analogues or KISQALI® reference-listed formulations — should treat US9868739B2 as a live clearance concern. The dismissal here resolved only the Novartis–Natco dispute and did not invalidate any claims. The patent remains in force and Novartis retains full enforcement rights against all other parties.
PatSnap Eureka’s FTO Search Agent allows IP teams to map the full claim scope of US9868739B2 against proposed compound structures and formulations, identify design-around opportunities, and surface the broader Novartis–Astex ribociclib portfolio in a single workflow. For teams tracking Hatch-Waxman exclusivity windows, Eureka can cross-reference FDA Orange Book listings with live patent status data to flag emerging enforcement risks before an ANDA filing.
Run a freedom-to-operate analysis on US9868739B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman CDK4/6 Inhibitor Patent Cases in Delaware
Cases involving CDK4/6 inhibitor compound patents litigated in Delaware District Court under the Hatch-Waxman framework — sorted by outcome and resolution speed.
What this case signals for the CDK4/6 inhibitor IP landscape
A 139-day Hatch-Waxman exit with prejudice and no public terms is a significant data point for any pharma competitor watching the KISQALI® exclusivity timeline.
Speed of resolution suggests a private agreement shielded from the public record
Hatch-Waxman suits rarely resolve in under five months without a commercial deal. The mutual cost-bearing arrangement and absence of any court order beyond the stipulation are consistent with a confidential license or agreed launch date. Generic entrants and IP counsel should treat the public record as incomplete.
Dismissal with prejudice does not extinguish the KISQALI® patent portfolio
US9868739B2 was the only patent asserted in this action. Novartis may hold additional issued or pending patents covering ribociclib formulations, methods of treatment, or manufacturing processes. Any generic developer targeting KISQALI® should conduct a full FTO sweep beyond this single patent number.
Novartis v Natco — key questions answered
Dismissal with prejudice under FRCP 41(a)(1)(A)(ii) bars Novartis and Astex Therapeutics from re-filing the same infringement claims against the three named Natco entities on US9868739B2. It does not affect Novartis’s right to sue other generic manufacturers, nor does it invalidate the patent.
Novartis asserted US9868739B2, filed under application number US14/887790, covering ribociclib — the CDK4/6 inhibitor active ingredient in KISQALI® tablets approved for hormone receptor-positive advanced breast cancer.
The 139-day resolution is notably short for Hatch-Waxman ANDA litigation. The public record shows only a stipulated dismissal with mutual cost-bearing and no court-ordered terms. This pattern is consistent with a confidential commercial resolution — such as a license or agreed launch date — though no such agreement appears in the public record.
Filing the suit in December 2024 would ordinarily trigger a 30-month Hatch-Waxman stay running to approximately June 2027. Dismissal before that window closed may suggest the parties negotiated a specific entry date or that Natco received a covenant not to sue. Monitoring FDA Orange Book patent listings for ribociclib can help track developments.
Yes. The with-prejudice bar applies only to the named Natco entities. Novartis and Astex Therapeutics retain full enforcement rights against any other ANDA applicant referencing KISQALI®. The patent’s validity was never tested in this action, leaving it fully enforceable against third parties.
PatSnap Eureka searches patents and litigation data to answer instantly.